Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.39 |
| ▸ | HTR2B | P41595 | 14/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596572 | 0.93 | HTR2B (0.38) | HTR2CHTR2BHTR2ANOS1NOS2 | |
| SCHEMBL5596313 | 0.93 | HTR2C (0.37) | HTR2CHTR2BHTR2ANOS1NOS2 | |
| SCHEMBL5418084 | 0.79 | HTR2C (0.47) | HTR2CHTR2BHTR2ANOS1NOS2 | |
| SCHEMBL5596774 | 0.76 | — | — | |
| SCHEMBL5597254 | 0.76 | PARP1 (0.33) | — | |
| SCHEMBL5597030 | 0.76 | PRKCZ (0.34) | PRKCZ | |
| SCHEMBL5597136 | 0.72 | HTR2C (0.47) | HTR2CHTR2BHTR2ANOS1NOS2 | |
| SCHEMBL5596723 | 0.72 | HTR2C (0.45) | HTR2CHTR2BHTR2ANOS1NOS2 | |
| SCHEMBL5597039 | 0.71 | FPR2 (0.41) | PIK3R1PIK3CA | |
| SCHEMBL5410387 | 0.71 | HTR2C (0.47) | HTR2CHTR2BHTR2ANOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | HTR2C 1430/4885HTR2B 1795/4885HTR2A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.